Eli Lilly stock: fundamental analysis
Stocks · LLY · Healthcare
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. Below are its fundamentals, explained in the order worth reading them: business quality, debt, growth and, last, whether the price is reasonable.
- Price: 1,152.93 USD
- Market cap: 1.0T USD
Data as of September 18, 2026 · Yahoo Finance
Quick read
Business quality
ROE of 102.3%: it earns a high return on shareholders' money. An ROE this high is usually driven by debt or buybacks, not only by the business. Out of every 100 in sales, 33.5 end up as profit.
Financial health
Net debt/EBITDA of 1.1x: it could repay its debt with less than two years of operating profit. Comfortable leverage.
Growth
Revenue is growing 47.7% year on year: a solid pace. Earnings are up 26.2%.
Valuation
It trades at a P/E of 38.8, in line with the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 24.4: the market expects profits to rise.
Dividend
Dividend yield of 0.6% (6.92 USD per share per year) with a payout ratio of 21.7%.
Tools
All metrics
| Eli Lilly | Sector median | |
|---|---|---|
| Business quality | ||
| ROE | 102.3% | 25.7% |
| ROA | 20.4% | 9.0% |
| Gross margin | 83.4% | 70.5% |
| Operating margin | 54.2% | 28.5% |
| Net margin | 33.5% | 15.6% |
| Financial health | ||
| Net debt/EBITDA | 1.1x | 2.0x |
| Debt/equity | 1.6x | 0.7x |
| Current ratio | 1.4x | 1.3x |
| Growth | ||
| Revenue growth | 47.7% | 10.2% |
| Earnings growth | 26.2% | 139.8% |
| Valuation | ||
| P/E ratio | 38.8x | 33.9x |
| Forward P/E | 24.4x | 16.7x |
| EV/EBITDA | 25.7x | 17.0x |
| Price/book | 30.3x | 4.2x |
| FCF yield | 1.1% | 4.7% |
| Dividend | ||
| Dividend yield | 0.6% | 1.8% |
| Payout ratio | 21.7% | 48.0% |
| Beta (volatility) | 0.5x | 0.3x |
Frequently asked questions
What is Eli Lilly's P/E ratio?
Eli Lilly's P/E is 38.8 based on trailing 12-month earnings and 24.4 on expected earnings. The median for its sector among the companies we track is 33.9. Data as of September 18, 2026.
What dividend does Eli Lilly pay?
Dividend yield of 0.6% (6.92 USD per share per year) with a payout ratio of 21.7%.
Is Eli Lilly stock expensive?
It trades at a P/E of 38.8, in line with the 33.9 median of the healthcare companies we track. On expected earnings the P/E falls to 24.4: the market expects profits to rise. This is an educational reading based on ratios, not a buy or sell recommendation.
Does Eli Lilly have a lot of debt?
Net debt/EBITDA of 1.1x: it could repay its debt with less than two years of operating profit. Comfortable leverage.
What is Eli Lilly's market cap?
Eli Lilly has a market cap of 1.0T USD and its shares trade at 1,152.93 USD, with a 52-week range of 712.05 USD to 1,292.65 USD (data as of September 18, 2026).
Other companies in the sector
Trailing 12-month metrics. Educational content, not investment advice.